Goethe University Frankfurt
Verified site
Frankfurt, Germany
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on two chronic intestinal conditions, Crohn's Disease and Ulcerative Colitis. These diseases cause inflammation of the digestive tract, leading to abdominal pain, diarrhea, and weight loss. The treatments being tested include a drug called risankizumab, an injectable medicine that targets specific immune cells, and a second agent named ABBV-701, also given by injection. A combination product identified as ABBV-7066 (risankizumab/ABBV-701) will be evaluated together, as well as each medication alone and a placebo.
The purpose of the study is to compare how well the combination works against the individual medicines in adults with moderately to severely active disease. Participants will receive a series of subcutaneous injections (a shot under the skin) or an intravenous infusion (medicine delivered through a vein) over several weeks. During the trial, doctors will look inside the intestine using a camera (endoscopy) to see if the lining has healed, a state called endoscopic remission, and will also record symptoms such as stool frequency and abdominal pain to assess clinical improvement.
Throughout the study, participants will be monitored for any side effects, referred to as adverse events, and will have regular visits to check their health status. The overall study period lasts several months, allowing researchers to gather information on both safety and how effectively the medicines reduce disease activity.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
9 criteria
8 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Frankfurt, Germany
Leuven, Belgium
Gent, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
This medication is given as a subcutaneous injection in a clear solution for injection. It is an investigational drug that is currently being studied in clinical trials and is not yet approved for routine medical use. The trial is testing it for adults with moderately to severely active Crohn’s disease or ulcerative colitis, either alone or together with another drug. ABBV‑701 works by targeting a specific protein that helps control inflammation, and it belongs to the class of experimental biologic therapies.
Risankizumab is administered either as a subcutaneous injection or as an intravenous infusion, both using a sterile solution prepared for injection. It is an approved monoclonal antibody that blocks the interleukin‑23 (IL‑23) protein, reducing the inflammatory signals that drive disease. The drug is used to treat moderate to severe Crohn’s disease and ulcerative colitis, and it is classified as an immunosuppressive biologic agent. In the study it is examined both alone and in combination with ABBV‑701 to see if the combination works better.
Crohn's disease is a chronic condition that causes inflammation of the digestive tract, often affecting the end of the small intestine and the beginning of the colon. The inflammation may spread deep into the layers of the bowel wall, leading to pain, diarrhea, and weight loss. Over time, the affected areas can become narrowed or develop abnormal connections called fistulas. Symptoms may come and go, with periods of worsening followed by quieter phases. The disease can involve any part of the gastrointestinal tract, so its pattern of spread varies between individuals.
Ulcerative colitis is a long‑lasting disorder that inflames the lining of the large intestine, starting in the rectum and potentially extending upward through the colon. The inflamed lining develops tiny sores that cause frequent, urgent bowel movements and blood in the stool. As the condition continues, the colon may become thinner and lose its normal shape, leading to more frequent symptoms. The disease typically follows a pattern of flare‑ups and periods of relative calm. It is limited to the colon and does not affect other parts of the digestive system.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.